VT-1598 (oral gavage; 5, 15, and 50mg/kg; once daily; 7 d) treatment shows a significant and dose-dependent survival advantage, and dose-dependent reductions in fungal burden[1].
VT-1598 (oral gavage; 3.2, 8, and 20mg/kg; once daily; 4 d) is present to a great extent in the plasma and tongue after oral administration in Act1-deficient mice infected with C. albicans[2].
| Animal Model: | Mice model of invasive candidiasis[1] |
| Dosage: | 5, 15, and 50mg/kg |
| Administration: | Oral gavage; once daily; 7 days |
| Result: | Observed median survival in the VT-1598 15 mg/kg and 50 mg/kg groups (15days and >21days, respectively) longer than the control group.
Observed kidney fungal burden in mice treated with 15 mg/kg and 50 mg/kg doses (mean log10 CFU/g, 5.40 and 3.67, respectively) lower than the vehicle control group.
Showed mean trough concentrations 1.55μg/mL after 7days of therapy in the 5 mg/kg group, 6.78μg/mL in the 15 mg/kg group, and 14.2μg/mL in the 50 mg/kg group.
|
| Animal Model: | Act1-deficient mice infected with C. albicans[2] |
| Dosage: | 3.2, 8, and 20mg/kg |
| Administration: | Oral gavage; once daily; 4 days |
| Result: | Resulted in high concentrations in the plasma and tongues of Candida-infected mice. |
